Kezar files to raise $80.5M in IPO on NASDAQ

Kezar Life Sciences Inc. (South San Francisco, Calif.) filed May 24 to raise $80.5 million in an IPO on NASDAQ underwritten by Jefferies, Cowen, Wells Fargo and William Blair.

Kezar is developing immunoproteasome-targeted therapeutics to selectively suppress the hyperactive immune cells that drive autoimmunity. It was spun out from the Onyx Pharmaceuticals Inc. subsidiary of Amgen Inc. (NASDAQ:AMGN) in 2015 (see BioCentury, Sept 22, 2017)...